Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors

Therapeutic approaches are needed to promote T cell-mediated destruction of poorly immunogenic, cold tumors typically associated with minimal response to immune checkpoint blockade (ICB) therapy. Bispecific T cell engager (BiTE) molecules induce redirected lysis of cancer cells by polyclonal T cells and have demonstrated promising clinical activity against solid tumors in some patients. However, little is understood about the key factors that govern clinical responses to these therapies. Using an immunocompetent mouse model expressing a humanized CD3. chain (huCD3e mice) and BiTE molecules directed against mouse CD19, mouse CLDN18.2, or human EPCAM antigens, we investigated the pharmacokinetic and pharmacodynamic parameters and immune correlates associated with BiTE efficacy across multiple syngeneic solid-tumor models. These studies demonstrated that pretreatment tumor-associated T cell density is a critical determinant of response to BiTE therapy, identified CD8+ T cells as important targets and mediators of BiTE activity, and revealed an antagonistic role for CD4(+) T cells in BiTE efficacy. We also identified therapeutic combinations, including ICB and 4-1BB agonism, that synergized with BiTE treatment in poorly T cell-infiltrated, immunotherapy-refractory tumors. In these models, BiTE efficacy was dependent on local expansion of tumor-associated CD8(+) T cells, rather than their recruitment from circulation. Our findings highlight the relative contributions of baseline T cell infiltration, local T cell proliferation, and peripheral T cell trafficking for BiTE molecule-mediated efficacy, identify combination strategies capable of overcoming resistance to BiTE therapy, and have clinical relevance for the development of BiTE and other T cell engager therapies.

Automated summary

Our study in immunocompetent mouse models revealed that pretreatment tumor-associated T cell density is a critical factor in determining response to BiTE therapy. CD8+ T cells were identified as important targets and mediators of BiTE activity, while CD4(+) T cells played an antagonistic role in BiTE efficacy. In addition, therapeutic combinations such as ICB and 4-1BB agonism were found to synergize with BiTE treatment in poorly T cell-infiltrated, immunotherapy-refractory tumors.